TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neuropathic pain of peripheral origin demonstrating spontaneous ongoing pain and dynamic mechanical allodynia to brush stimuli.~* A present pain intensity score of 4 or more (out of 10) for spontaneous ongoing pain and brush-evoked allodynia at the skin area at screen.~* Stable analgesic medication (excluding pregabalin) for a minimum of 1 month prior to the start of study.~Exclusion Criteria:~* Patients who have undergone neurolytic or neurosurgical therapy.~* Patients who have trigeminal neuralgia, central pain (due to cerebrovascular lesions, multiple sclerosis and traumatic spinal cord injuries), complex regional pain syndrome (Type I and II), and phantom limb pain.~* Patients who have previously been treated with pregabalin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active drug (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing in vitro fertilization~Exclusion Criteria:~* risk of ovarian hyperstimulation syndrome

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bravelle
- 2 (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin for Prevention of Travellers' Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. travelling to Mexico within 72 hours of enrollment~2. read and understand English~3. in good health~Exclusion Criteria:~1. acute diarrhea within previous 7 days~2. taken FQs (any drug in this class), macrolide, azalide, or trimethoprim-sulfamethoxazole within 7 days or enrollment or anytime during study.~3. taken antidiarrheal medication within 24 hours of enrollment or anytime during study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Rifaximin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FMS European Long-Term Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patient who completed the 3-month F02207 GE 302 study~* patient with a diagnosis of fibromyalgia according to the 1990 ACR criteria at entry of F02207 GE 302 study~Exclusion Criteria:~* known hypersensitivity to milnacipran~* major depressive episode~* significant risk of suicide~* generalised anxiety disorder~* substance abuse~* clinically significant cardiac disease~* pulmonary dysfunction~* active liver disease~* renal impairment~* autoimmune disease~* current systemic infection~* epileptic~* active cancer~* severe sleep apnoea~* active peptic ulcer~* inflammatory bowel disease~* unstable endocrine disease~* (for men) prostatic enlargement or other genito-urinary disorders~* (for women) pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 71 Years
- Healthy Volunteers: f

Study Arms:
- Minalcipran 100 mg (Type: EXPERIMENTAL): None
- Minalcipran 150 mg (Type: EXPERIMENTAL): None
- Minalcipran 200 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/= 18 years of age~* moderate to severe active rheumatoid arthritis of \>/=6 months duration~* inadequate clinical response to current non-biologic DMARDs~* current DMARDs must be at stable dose for 8 weeks prior to study entry~* oral corticosteroids (\</=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for \>/=4 weeks prior to screening~Exclusion Criteria:~* rheumatic autoimmune disease other than RA~* history of or current inflammatory joint disease other than RA~* previous treatment with any biologic DMARD~* functional class IV as defined by the ACR classification~* intra-articular or parenteral corticosteroids within 6 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Concomitant alone (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
- Concomitant +Mixed (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
- Concomitant +MF59-eH5N1 (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
- Mixed (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
- Mixed and mixed (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
- Mixed+MF59-eH5N1 (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
- MF59-eH5N1+eTIV_a (Type: EXPERIMENTAL): 1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
- eTIV_a+MF59-eH5N1 (Type: EXPERIMENTAL): 1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of leukemia or myelodysplastic syndromes (MDS) meeting criteria for 1 of the following:~  * Relapsed or refractory leukemia for which there is no standard therapy anticipated to result in a durable remission~    * Acute myeloid leukemia~   * Acute lymphocytic leukemia~   * Chronic myelogenous leukemia~      * In blast crisis~ * Untreated leukemia and standard therapy is refused~ * Any of the following poor-risk MDS:~    * Refractory anemia with excess blasts (RAEB)~   * RAEB in transformation~   * Chronic myelomonocytic leukemia~* CNS leukemia allowed~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* ALT or AST no greater than 3 times ULN~* Chronic hepatitis allowed~Renal~* Creatinine no greater than 2.0 mg/dL~Cardiovascular~* No active heart disease~* No myocardial infarction within the past 3 months~* No symptomatic coronary artery disease~* No arrhythmias uncontrolled by medication~* No uncontrolled congestive heart failure~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No persistent chronic toxic effects from prior chemotherapy greater than grade 1~* No uncontrolled active infection~  * Infections under control and under active treatment with antibiotics allowed~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 48 hours since prior hydroxyurea~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* At least 2 weeks since prior myelosuppressive cytotoxic agents (in the absence of rapidly progressing disease)~* No other concurrent standard or investigational treatment for leukemia~* No concurrent disulfiram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of T2DM~* Treated with basal insulin for ≥ 6 months, with current dose stable for ≥ 6 weeks of ≥ 0.3 U/kg/day, with or without anti-hyperglycemic agents and in whom the Investigator feels advancement from basal to basal and bolus therapy is needed for the patient~* A1C 7.5-11.0% by central lab value at screening visit~* Already perform self-monitoring of blood glucose (SMBG) and willing to test blood glucose (BG) over the course of the study~* Body Mass Index of ≤ 40 kg/m2~Exclusion Criteria:~* Currently on or has been treated in the past year with insulin regimens that include bolus insulins except the need for insulins in the settings of acute illness or hospitalization~* History of type 1 diabetes mellitus (T1DM), or diabetic ketoacidosis (DKA), or secondary forms of diabetes such as cystic fibrosis~* Known hypersensitivity or allergy to insulin-glargine or its excipients or any other insulins~* Two or more severe hypoglycemic episodes within the prior year~* Hypoglycemia unawareness defined by history~* History of proliferative diabetic retinopathy~* Is currently unstable and/or has moderate-to-severe medical illness in the Investigator's judgment~* Uncontrolled hypertension (either treated or untreated) defined as a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 100 mmHg at screening~* History of recent major surgery within 6 months, or minor surgery within 3 months (such as appendectomy) prior to screening visit, or a planned surgery during the study period~* History of bariatric surgery~* Active chronic infections~* Women of child-bearing age who are pregnant, planning pregnancy, breast-feeding, or, if capable of pregnancy, are not practicing contraception if heterosexually active~* Known hypersensitivity to plastics/polymers/adhesives~* Known difficulties with adherence of adhesives, bandages, or dressings~* Participated in any research study within the past 30 days~* Currently participating in another investigational trial~* Use of short term or chronic systemic steroids within three months of entry into the study or likelihood that same might be required during the conduct of the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bolus Insulin Patch (Calibra Finesse) (Type: EXPERIMENTAL): Use of the wearable patch to deliver meal-related bolus insulin dose
- Insulin Pen (Novo-Nordisk FlexPen®) (Type: ACTIVE_COMPARATOR): Use of the pen device to deliver meal-related bolus insulin dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Tolerability of Avonex Intramuscular Injections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 - 65 years of age;~* Confirmed diagnosis of Relapsing Remitting Multiple Sclerosis;~* Currently being treated with Avonex® for at least 90 days;~* Using 25 gauge needles for injection of Avonex® for at least 90 days;~* Willing and able to complete study questionnaires; and~* Provided informed consent to participate in this study~Exclusion Criteria:~* Diagnosis of Progressive Multiple Sclerosis;~* History of recent illness or infection;~* History of allergic reaction to Avonex®;~* Any prior usage of a 30 gauge needle for administration of Avonex®;~* Concurrent treatment with other immunomodulating therapies;~* Pregnant or planning on becoming pregnant;~* Nursing mothers; and~* Unable to complete the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 30 gauge (Type: EXPERIMENTAL): Subjects used a 30 gauge needle for intramuscular injection of Avonex.
- 25 gauge (Type: EXPERIMENTAL): Subjects used a 25 gauge needle for intramuscular injection of Avonex.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Social Anxiety Disorder and Selective Mutism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 4 to 7 year old children who meet diagnostic criteria for a primary diagnosis of Selective Mutism (SM) and/or Social Anxiety Disorder (SAD) through a clinical and semi-structured diagnostic interview .~* Presence of other anxiety disorders/symptoms is not an exclusion criterion as long as the main concern (primary diagnosis) is SAD and/or SM.~Exclusion Criteria:~* Presence of autism spectrum disorder, brain injury, or significant developmental delays (based on medical history and clinical assessment).~* Children and parents not fluent in English.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Taming Sneaky Fears Group (Type: EXPERIMENTAL): An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
- Parent Psychoeducation and Child Socialization Group (Type: ACTIVE_COMPARATOR): An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of DM2 = or \< 10 years~2. Age 21-65~3. BMI 27-32.~4. HBA1c ≥ 8%, on maximum treatment from primary care physician~5. At least one of the following co-morbidities on treatment: hypertension, hyperlipidaemia, micro/macro-proteinuria or ≤class I nephropathy, retinopathy.~Exclusion Criteria:~1. Subjects who had previous Bariatric surgery or extensive upper abdominal surgery~2. Pregnant subjects.~3. Nephropathy requiring dialysis~4. Subjects who are not fit for general anaesthesia.~5. Subjects who are unsuitable for RYGB for whatever reason, medical/surgical/psychological.~6. Subjects who are unwilling or possibly unable to participate in the follow up process.~7. Subjects who are reluctant to be randomised into the two study groups.~8. Subjects who suffers from unstable psychiatric illness~9. Subjects who are active substance abusers~10. Glutamic acid decarboxylase antibody positive.~11. fasting C-peptide \< 300 pmol/L

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Roux-en-Y Gastric Bypass (RYGB) (Type: ACTIVE_COMPARATOR): Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
- Best Medical Treatment (Type: ACTIVE_COMPARATOR): Anti-diabetic medications provided (Mono- or Combination- therapy):~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids \& BP medications according to standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 50 years~* smoking history \> 10 packs/year~* post-bronchodilator FEV1 between 30 and 80% predicted and FEV1/FVC \< 70% as assessed in previous pulmonary function test (GOLD stage II and III)~Exclusion Criteria:~* respiratory exacerbation within the preceding 2 months~* history of asthma~* significant O2 desaturation (SaO2 \< 85%) at rest or during exercise~* presence of another pathology that could influence exercise tolerance

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ipratropium bromide (Type: ACTIVE_COMPARATOR): acute bronchodilation: ipratropium bromide
- placebo (Type: PLACEBO_COMPARATOR): placebo nebulization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18 to 85 years of age~* Chronic or Non-healing ulcer of any etiology (venous, pressure, arterial or diabetic foot ulcer) which is at least 4 weeks old~* Index foot ulcer located on the plantar, medial or lateral aspect of the foot (including all toe surfaces)~* Wound area (length x width) measurement must be between 0.5 cm\^2 and 10 cm\^2, inclusive~* If more than one non-healing ulcers is present, the largest wound will be selected~* Index ulcer must be clinically non-infected~* Full-thickness ulcer without exposure of bone, muscle, ligament or tendon~* Written informed consent must be obtained from either the patient or the patients legally acceptable representative prior to enrollment~Exclusion Criteria:~* Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, acid citrate dextrose solution A (ACD-A))~* Smokers and individuals with systemic disease or history of anticoagulant, immuno-suppressive or antibiotic therapy in the last 3 months~* Platelet count \< 105 x 10\^3/ uL (according to CBC)~* Hemoglobin level \< 10 g/dL (according to CBC)~* Wound is clinically infected~* Presence of platelet dysfunction syndrome or critical thrombocytopenia~* Bleeding disorders, collagen vascular disease or severe cardiovascular disorder~* Any malignancy other than non-melanoma skin cancer~* Patient is currently receiving or has received radiation or chemotherapy within 3 months prior to treatment~* If female, patient is pregnant, nursing or plans to become pregnant during the duration of the study~* Subject has inadequate venous access for blood draw required for PRP preparation~* Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study~* Subject is on dialysis or has uncontrolled sugar levels

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Autologous PRP Gel and PRP Injection (Type: EXPERIMENTAL): Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete